1. Home
  2. LXU vs GERN Comparison

LXU vs GERN Comparison

Compare LXU & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LSB Industries Inc.

LXU

LSB Industries Inc.

HOLD

Current Price

$10.96

Market Cap

781.3M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.50

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXU
GERN
Founded
1968
1990
Country
United States
United States
Employees
513
258
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.3M
808.3M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
LXU
GERN
Price
$10.96
$1.50
Analyst Decision
Hold
Hold
Analyst Count
4
3
Target Price
$14.63
$2.17
AVG Volume (30 Days)
756.7K
14.0M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
225.93
N/A
EPS
0.27
N/A
Revenue
$615,208,000.00
N/A
Revenue This Year
$13.69
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
$40.41
N/A
Revenue Growth
17.77
N/A
52 Week Low
$7.09
$1.04
52 Week High
$17.22
$2.01

Technical Indicators

Market Signals
Indicator
LXU
GERN
Relative Strength Index (RSI) 40.02 65.05
Support Level $10.53 $1.44
Resistance Level $15.56 $1.72
Average True Range (ATR) 0.37 0.09
MACD 0.10 0.03
Stochastic Oscillator 48.02 68.06

Price Performance

Historical Comparison
LXU
GERN

About LXU LSB Industries Inc.

LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: